[HTML][HTML] Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer …
K Xiong, Y Yang, Y Yang, Z Wang, Y Liu, H Duo… - Neoplasia, 2024 - Elsevier
Abstract Background Tyrosine kinase inhibitors (TKIs) are standard first-line treatments for
advanced non-small-cell lung cancer (NSCLC) with driver gene mutations. The Response …
advanced non-small-cell lung cancer (NSCLC) with driver gene mutations. The Response …
Concurrent EGFR‐TKI and thoracic radiotherapy as first‐line treatment for stage IV non‐small cell lung cancer harboring EGFR active mutations
LP Zheng, Y Wang, Z Xu, Q Yang, G Zhu… - The …, 2019 - academic.oup.com
Abstract Lessons Learned This single‐arm, phase II study shows that concurrent EGFR‐
tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non …
tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non …
Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated …
Introduction Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-
free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene …
free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene …
[HTML][HTML] EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
J Xu, H Yang, B Jin, Y Lou, Y Zhang, X Zhang… - Scientific reports, 2016 - nature.com
The efficacy of EGFR tyrosine kinase inhibitors (TKIs) varies among different EGFR
mutations. Here, we directly compared the efficacy of first-line TKIs to chemotherapy for non …
mutations. Here, we directly compared the efficacy of first-line TKIs to chemotherapy for non …
[HTML][HTML] First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung …
X Hu, H Li, X Kang, X Wang, H Pang, C Liu… - Frontiers in …, 2022 - frontiersin.org
Background: The aim of this study was to investigate the efficacy and safety of combined
application of local consolidative radiation therapy (LCRT) and first-line tyrosine kinase …
application of local consolidative radiation therapy (LCRT) and first-line tyrosine kinase …
Targeting rare and non-canonical driver variants in NSCLC–An uncharted clinical field
AL Volckmar, P Christopoulos, M Kirchner, M Allgäuer… - Lung Cancer, 2021 - Elsevier
Objectives Implementation of tyrosine kinase inhibitors (TKI) and other targeted therapies
was a main advance in thoracic oncology with survival gains ranging from several months to …
was a main advance in thoracic oncology with survival gains ranging from several months to …
Prognostic significance of EGFR gene mutation in patients with EGFR mutated non-small cell lung cancer who received best supportive care alone
T Masuda, YU Wakabayashi, T Nakashima… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: The significance of epidermal growth factor receptor (EGFR) mutation in
untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to …
untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to …
[HTML][HTML] Outcome differences between first-and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort
SC Lau, N Chooback, C Ho, B Melosky - Clinical Lung Cancer, 2019 - Elsevier
Introduction Second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) appear superior to first-generation TKIs in clinical trials, but at the cost of …
inhibitors (TKIs) appear superior to first-generation TKIs in clinical trials, but at the cost of …
[HTML][HTML] Impact of EGFR mutation and ALK translocation on recurrence pattern after definitive chemoradiotherapy for inoperable stage III non-squamous non–small …
M Nakamura, S Kageyama, S Niho, M Okumura… - Clinical Lung Cancer, 2019 - Elsevier
Introduction This study was aimed at clarifying the failure pattern after definitive
chemoradiotherapy in patients with stage III non–small-cell lung cancer (NSCLC) harboring …
chemoradiotherapy in patients with stage III non–small-cell lung cancer (NSCLC) harboring …
Improvement in the survival of patients with stage IV non-small-cell lung cancer: experience in a single institutional 1995–2017
N Takano, R Ariyasu, J Koyama, T Sonoda, M Saiki… - Lung Cancer, 2019 - Elsevier
Objectives In the past two decades several antineoplastic agents have been approved for
the treatment of advanced non-small-cell lung cancer (NSCLC), and the management of …
the treatment of advanced non-small-cell lung cancer (NSCLC), and the management of …